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OBJECTIVE—Short adult stature has previously been associ-
ated with cardiovascular disease, but its relationship with the
microvascular complications of diabetes is uncertain. Therefore,
we evaluated the association between adult stature and preva-
lence and incidence of diabetic microvascular complications.
RESEARCH DESIGN AND METHODS—This cross-sectional
and longitudinal study comprises 3,968 adult patients with type 1
diabetes from the Finnish Diabetic Nephropathy (FinnDiane)
Study and 1,246 adult patients from the Diabetes Control and
Complications Trial (DCCT). In FinnDiane, diabetic nephropathy
was deﬁned as urinary albumin excretion 300 mg/24 h, dialysis,
or renal transplantation. Retinopathy was divided into back-
ground and proliferative (laser-treated) retinopathy. In the DCCT,
original nephropathy (class 1–6) and retinopathy (Early Treatment
of Diabetic Retinopathy Study) classiﬁcations were used.
RESULTS—In the FinnDiane study, patients in the lowest
quartile of adult height had increased risks of prevalent diabetic
nephropathy (odds ratio [OR] 1.71, 95% CI 1.44–2.02) and prev-
alent laser-treated retinopathy (1.66, 1.43–1.93) compared with
other patients. Similarly, in the DCCT, patients in the lowest
quartile of adult height had increased risks of incident diabetic
nephropathy class 4–6 (hazard ratio 2.70, 95% CI 1.59–4.59) and
incident proliferative retinopathy (2.06, 1.15–3.71). In the FinnDi-
ane study, the associations were largely explained by childhood
exposure to diabetes. However, in the DCCT, where a greater
proportion of patients had diabetes onset 18 years, the associ-
ation with nephropathy was independent of childhood diabetes
exposure.
CONCLUSIONS—Short adult stature is associated with micro-
vascular complications in patients with type 1 diabetes. These
ﬁndings are compatible with either childhood diabetes exposure
or “common soil” or both as potential explanations. Diabetes
58:1914–1920, 2009
D
espite advances in the treatment of patients
with type 1 diabetes, diabetic complications are
still a major concern as the main cause of
morbidity and mortality in patients with type 1
diabetes. The most devastating complication is diabetic
nephropathy, which is associated with a markedly in-
creased risk of end-stage renal failure, cardiovascular
disease (1), and premature death (2).
To prevent or delay the development of diabetic com-
plications, the identiﬁcation of high-risk patients who
would beneﬁt from intensive treatment and follow-up is
crucial. Established risk factors for diabetic nephropathy
include poor glycemic control, duration of diabetes, mi-
croalbuminuria, hypertension, male sex, ethnicity, and
smoking.
Epidemiological observations indicate that short adult
stature is associated with adverse health outcomes, par-
ticularly with cardiovascular disease (3). Short stature has
also been associated with hypertension and early arterial
stiffening (4), impaired glucose tolerance (5), type 2 dia-
betes (6), gestational diabetes (7), and pre-eclampsia (8).
Short stature may be a marker of unfavorable fetal devel-
opment and subsequent impaired growth in early child-
hood, factors that are associated with chronic disease in
adulthood (9). The pathogenesis of diabetic complications
shares several potential mechanisms with these condi-
tions, mainly endothelial dysfunction, chronic low-grade
inﬂammation, and insulin resistance. We recently showed
that pre-eclampsia is a risk factor for later development of
diabetic nephropathy in women with type 1 diabetes (10).
However, the association between short stature and dia-
betic complications is uncertain (11,12). Therefore, we
evaluated this association in two large cohorts of patients
with type 1 diabetes: the Finnish Diabetic Nephropathy
(FinnDiane) Study and the Diabetes Control and Compli-
cations Trial (DCCT).
RESEARCH DESIGN AND METHODS
The FinnDiane study. The present study includes cross-sectional data from
the ongoing FinnDiane study, a comprehensive, nationwide, multi-center
study with the aim to identify clinical, biochemical, environmental, and
genetic risk factors for diabetic nephropathy in type 1 diabetes. The partici-
pating centers represent outpatient clinics at four out of a total of ﬁve
university central hospitals, all central hospitals (n  16), the majority of all
regional hospitals (n  27), and 31 major primary health care centers. At
routine outpatient visits, patients with type 1 diabetes (ICD-10 code E10) were
asked to participate in the study. Height was measured using a wall-mounted
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1914 DIABETES, VOL. 58, AUGUST 2009stadiometer and weight was measured wearing light clothing. Waist and hip
circumferences and blood pressure were measured. Based on medical
records, the attending physician completed a standardized check-list regard-
ing diabetic complications and medication. Data on smoking (current and
previous) and social class (grouped as unskilled/skilled blue collar, unskilled/
skilled white collar, farmers, and others) were collected in a self-report
questionnaire. Written informed consent was obtained from each patient, and
the study protocol was conducted in accordance with the Declaration of
Helsinki.
Values for the three most recent urinary albumin excretion rates (UAERs)
in timed urine collections were obtained from the study centers. In addition,
one 24-h urine collection was completed in which UAER was measured
centrally using radioimmunoassay and immunoturbidimetry from 2002. Mac-
roalbuminuria was deﬁned as UAER 300 mg/24 h or 200 g/min in at least
two out of three consecutive urine collections. Corresponding UAER values
for microalbuminuria were 30  300 mg/24 h or 20  200 g/min.
End-stage renal disease (ESRD) was deﬁned as hemodialysis, peritoneal
dialysis, or renal transplantation. Diabetic nephropathy was deﬁned as mac-
roalbuminuria or ESRD. Data on retinopathy were obtained from medical
records and classiﬁed as background or proliferative (laser-treated) retinop-
athy. Cardiovascular disease (CVD) was deﬁned as a history of symptomatic
coronary heart disease, myocardial infarction, a coronary artery procedure
(bypass surgery or angioplasty), stroke, limb amputation, or a peripheral
artery procedure.
Renal function (estimated glomerular ﬁltration rate [eGFR]) was calculated
with the Cockcroft-Gault formula corrected for body surface area (13). Insulin
sensitivity was calculated with the formula for estimated glucose disposal rate
(eGDR) (14). The latest A1C value was obtained from the study centers.
In this analysis, the criteria for type 1 diabetes were age at diagnosis of
diabetes 35 years and permanent insulin treatment initiation within 1 year of
diagnosis. Patients 18 years of age (n  78) were excluded from the analyses
because of possible ongoing linear growth. In the FinnDiane database, data on
height were available for 3,968 adult patients with type 1 diabetes.
The DCCT. To replicate the results from the FinnDiane Study, we used
publicly available data from the DCCT, available at http://www.gcrc.umn.edu/
gcrc/downloads/dcct.html. In brief, the DCCT was a randomized intervention
study of 1,441 patients aged 13–39 years designed to compare intensive versus
conventional blood glucose management on the development of diabetic
complications in patients with type 1 diabetes (15). At baseline, none of the
patients had diabetic nephropathy. Renal status was classiﬁed as nephropathy
class 1–6 as follows: class 1, UAER 40 mg/24 h; class 2, 40–70 mg/24 h; class
3, 70–200 mg/24 h; class 4, 200–300 mg/24 h; class 5, 300 mg/24 h; class 6,
300 mg/24 h plus GFR 70 ml/min per 1.73 m
2. Progression in renal status
was deﬁned according to the highest renal class observed during follow-up.
Retinopathy was graded with the abbreviated ﬁnal version of the ETDRS scale
of diabetic retinopathy severity, consisting of step 1–23 for individual persons,
which in turn was based on ETDRS level 10–85 for individual eyes (16). Data
on height were complete. Patients 18 years of age at study entry (n  195)
were excluded because of possible ongoing linear growth, leaving 1,246
patients eligible for the analyses.
Statistical analyses. SPSS version 15.0.1 software (SPSS, Chicago, IL) was
used for statistical analysis. Height was used both as a continuous variable
and as a categorical variable divided into quartiles separately for each decade
of birth in the FinnDiane data to minimize the effect of a secular increase in
height. Continuous variables were expressed as mean  SD or median
(interquartile range). Categorical variables were reported as percentage.
Differences between quartiles of height were analyzed by ANOVA for normally
distributed continuous variables; otherwise, the Kruskal-Wallis was used. For
categorical variables, the 
2 test was used. Whenever P values were adjusted
for age or duration of diabetes, ANCOVA and logistic regression were used for
continuous and categorical variables, respectively. In cross-sectional data,
multiple logistic regression was used as multivariate analysis. Longitudinal
data were analyzed by Cox proportional hazard survival regression.
RESULTS
The FinnDiane study. Data on height were available for
3,968 adult patients with type 1 diabetes (2,032 men, 1,936
women), with a mean age of 37.8  11.5 years (range
18.0–77.9), duration of diabetes 23.0  12.0 years, BMI
25.0  3.5 kg/m
2, and A1C 8.5  1.5%. Mean height was
177.3  7.0 cm in men and 164.1  6.3 cm in women. Mean
age at onset of diabetes was 14.8  8.5 years and 18
years in 67.4% of the patients. There was a secular trend of
greater adult height in more recent birth cohorts (data not
shown). Of the patients, 56.7% had normal UAER, 12.5%
had microalbuminuria, 14.5% had macroalbuminuria, and
6.9% had ESRD. In 9.4% of the patients, renal status could
not yet be deﬁned because of an insufﬁcient number of
urine collections; 35.3% of patients had laser-treated reti-
nopathy and 9.8% had CVD.
Clinical characteristics according to quartiles of height
are presented in Table 1. Shorter stature was associated
with worse glycemic control and blood lipid proﬁle, higher
prevalence of antihypertensive medication, higher insulin
dose per body weight, and importantly a higher prevalence
of microalbuminuria, diabetic nephropathy, laser-treated
retinopathy, and CVD. There were no differences in age
between quartiles of height because of stratiﬁcation for
decade of birth, but there were, however, differences in
the duration of diabetes across quartiles of height because
of differences in age at onset of diabetes. After further
adjustment for duration of diabetes, there were still signif-
icant associations between short stature and diabetic
nephropathy and retinopathy, but not with CVD. In sup-
plementary Table 1 (available in the online-only appen-
dix at http://diabetes.diabetesjournals.org/cgi/content/full/
db08-1767/DC1), absolute values for height according to
complication status are given for men and women, show-
ing a shorter stature beginning at the level of microalbu-
minuria compared with normoalbuminuria for both sexes.
The time from diagnosis of diabetes to nephropathy did
not differ across quartiles of height (P  0.395). Similarly,
there was no difference in time to the ﬁrst laser treatment
for proliferative retinopathy (P  0.675). Height correlated
with UAER and eGFR in men (Spearman r  0.11 and
0.18, respectively, P  0.001 for both) and in women (r 
0.10 and 0.13, respectively, P  0.001 for both).
To adjust for possible confounding factors, multiple
logistic regression analyses were undertaken (Table 2), in
which short stature was independently associated with
both diabetic nephropathy and laser-treated retinopathy in
addition to the conventional risk factors duration of
diabetes, A1C, blood pressure, male sex, smoking, and
social class.
To explore the possibility of a cohort effect, we further
analyzed the prevalence of nephropathy and retinopathy
by height quartile and decade of birth (Fig. 1A and B),
showing a consistent association over time. Moreover,
there was still an association between higher prevalence
of laser-treated retinopathy and short stature after exclu-
sion of patients with diabetic nephropathy (Fig. 1C).
Age at onset of diabetes was associated with adult
stature (Table 1). Therefore, we divided the patients based
on age at onset of diabetes (Fig. 1D). We observed an
association between higher prevalence of nephropathy
and a shorter stature in patients who had developed
diabetes at 5 and 5–12.9 years of age, whereas no evident
association between adult stature and nephropathy was
seen in the group of 13–18 years at onset (Fig. 1D). The
results for retinopathy were similar as for nephropathy
(data not shown). In patients 18 years at diabetes onset,
there was a nonsigniﬁcant trend toward a higher preva-
lence of nephropathy in patients with short stature: 17.0
versus 11.9% in 1st quartile versus 2nd–4th quartiles (P 
0.058). Furthermore, when we additionally adjusted for
years of diabetes exposure during the years of linear
growth (i.e., years of diabetes before age 18 years) in the
logistic regression model in Table 2, adult stature was no
longer associated with nephropathy or retinopathy. Be-
cause of possible collinearity between the diabetes dura-
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from the ﬁnal model (model 9), which did not change the
main results (not shown).
The DCCT. Of the eligible 1,246 patients, 666 were men
and 580 women, and 96.8% were white. At baseline, mean
age was 28.7  5.7 years (range 18–39), duration of
diabetes 5.8  4.3 years, BMI 23.6  2.8 kg/m
2, and A1C
8.8  1.5%. Mean height was 178.7  7.1 cm in men and
164.9  6.1 cm in women. Mean age at onset of diabetes
was 22.9  7.2 years and 18 years in 25.6% of the
patients.
Short stature was associated with lower age at onset of
diabetes, longer duration of diabetes, and higher insulin
dose per body weight (Table 3). At baseline, stature was
not associated with renal status (Table 3). However, none
of the patients had nephropathy because baseline ne-
phropathy was an exclusion criterion in the DCCT. At
close-out, 8.4% of patients within the lowest quartile of
height had developed nephropathy class 4–6 compared
with 3.1% in the top three quartiles (P  0.001). In patients
diagnosed with diabetes after the age of 18 years, corre-
sponding proportions were 5.4 and 2.5% (P  0.039),
respectively. In a Cox regression model for progression to
nephropathy class 4–6, patients within the lowest quartile
of height had a 2.39-fold higher risk of nephropathy when
adjusting for conventional risk factors and the duration of
TABLE 1
Clinical characteristics by birth decade–speciﬁc quartiles of height in the FinnDiane Study
Quartile
P
P adjusted for
duration of
diabetes 1st 2nd 3rd 4th
Number of patients 984 998 990 996 NA NA
Age (years) 37.5  11.5 38.0  11.6 37.8  11.5 37.8  11.3 0.81 NA
Sex (% men) 51.9 51.3 50.1 51.5 0.87 NA
Blue-collar workers (%) 70.2 66.2 63.1 56.5 1  10
5 1  10
5
Ever smoke (%) 48.0 45.8 48.8 43.5 0.09 0.16
Age at onset of diabetes (years) 11.9  8.2 14.5  8.5 15.9  8.2 16.7  8.1 1  10
5 NA
Duration of diabetes (years) 25.6  12.2 23.4  12.1 22.0  11.7 21.1  11.6 1  10
5 NA
A1C (%) 8.6  1.6 8.5  1.5 8.4  1.5 8.3  1.4 1  10
2 1  10
2
Insulin dose (IU/kg) 0.75  0.28 0.72  0.25 0.70  0.22 0.68  0.23 1  10
5 1  10
5
eGDR (mg  kg
1  min
1) 5.5 (4.0–8.1) 6.0 (4.3–8.3) 6.2 (4.3–8.5) 6.6 (4.5–8.8) 1  10
5 0.27
Systolic blood pressure (mmHg) 135  20 135  19 134  18 133  18 0.06 0.62
Diastolic blood pressure (mmHg) 79  10 80  10 80  10 80  10 0.56 0.60
Antihypertensive medication (%) 47.9 41.5 36.1 33.4 1  10
5 1  10
3
BMI (kg/m
2) 25.1  3.6 25.1  3.6 25.0  3.5 24.9  3.4 0.33 0.52
Waist-to-hip ratio 0.87  0.09 0.87  0.09 0.86  0.08 0.87  0.08 0.08 0.49
Total cholesterol (mmol/l) 5.1  1.1 4.9  0.9 5.0  1.2 4.9  1.0 1  10
2 0.08
Triglycerides (mmol/l) 1.11 (0.81–1.62) 1.06 (0.80–1.48) 1.00 (0.75–1.43) 0.98 (0.75–1.37) 1  10
5 1  10
5
Lipid-lowering medication (%) 13.7 11.5 9.4 9.6 1  10
2 0.37
UAER (mg/24 h) (n  2,697) 15.0 (6.6–108.5) 12.2 (6.1–51.7) 10.8 (6.0–45.8) 10.6 (5.8–26.8) 1  10
5 1  10
2
eGFR (ml/min per 1.73 m
2) 86  34 93  48 92  31 97  43 1  10
5 0.02
Microalbuminuria (%) 15.2 14.4 9.4 10.9 1  10
3 1  10
2
Macroalbuminuria (%) 18.3 14.9 13.5 11.3 1  10
3 0.01
End-stage renal disease (%) 10.0 6.2 6.3 5.0 1  10
4 0.03
Diabetic nephropathy (%) 28.3 21.1 19.8 16.3 1  10
5 1  10
3
Laser-treated retinopathy (%) 44.4 38.7 31.3 27.5 1  10
5 1  10
5
Laser-treated retinopathy, normal
UAER (%) 18.7 16.2 14.1 11.3 1  10
2 0.10
Cardiovascular disease (%) 12.8 9.3 9.2 8.2 1  10
2 0.93
Data are means  SD, median (interquartile range), or percentage as appropriate. NA, not applicable.
TABLE 2
Multivariate associations (logistic regression) of 1st quartile of decade of birth–speciﬁc quartile of height with diabetic nephropathy
and laser-treated retinopathy in the FinnDiane Study
Diabetic nephropathy Laser-treated retinopathy
OR (95% CI) P OR (95% CI) P
Model 1: unadjusted 1.71 (1.44–2.02) 0.001 1.66 (1.43–1.93) 0.001
Model 2: model 1 	 male sex 1.70 (1.44–2.02) 0.001 1.66 (1.43–1.93) 0.001
Model 3: model 2 	 duration of diabetes (years) 1.39 (1.16–1.67) 0.001 1.33 (1.11–1.58) 0.002
Model 4: model 3 	 A1C (%) 1.32 (1.10–1.60) 0.004 1.28 (1.07–1.54) 0.008
Model 5: model 4 	 systolic blood pressure (mmHg) 1.41 (1.16–1.73) 0.001 1.31 (1.09–1.58) 0.005
Model 6: model 5 	 ever smoke 1.36 (1.11–1.67) 0.003 1.31 (1.08–1.58) 0.006
Model 7: model 6 	 blue-collar worker 1.35 (1.08–1.68) 0.008 1.28 (1.05–1.57) 0.015
Model 8: model 7 	 BMI (kg/m
2) 1.35 (1.08–1.68) 0.008 1.28 (1.05–1.57) 0.016
Model 9: model 8 	 duration of diabetes (years) 18 years 1.12 (0.89–1.41) 0.338 1.12 (0.91–1.38) 0.273
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total duration of diabetes from the ﬁnal model (model 11)
did not change the main results (not shown).
At baseline, stature was not associated with retinopathy
status, but at close-out, a higher proportion of patients
within the lowest quartile of height had developed ETDRS
step 6 (minimum of background retinopathy, 21.8 vs.
14.0%, P  0.001) and ETDRS step 12 (minimum of mild
proliferative retinopathy, 6.3 vs. 2.9%, P  0.008) com-
pared with the top three quartiles (Table 3). In patients
diagnosed with diabetes after the age of 18 years, corre-
sponding proportions were 12.4 versus 10.1% (P  0.360)
for ETDRS step 6 and 2.0 versus 1.1% for ETDRS step
12 (P  0.346). In a Cox regression model, stature was
not independently associated with development of ETDRS
12 during follow-up (Table 4). For neuropathy (DCCT
analytic deﬁnition), in contrast to nephropathy and reti-
nopathy, tall stature was associated with higher preva-
lence (Table 3).
DISCUSSION
In the FinnDiane Study, we show a consistent association
between short adult stature and higher prevalence of
diabetic nephropathy and retinopathy in men and women
with type 1 diabetes. We also show that short stature is
associated with higher prevalence of microalbuminuria.
Furthermore, short stature is associated with proliferative
retinopathy, even when patients with diabetic nephropa-
thy are excluded, indicating that the association with
retinopathy is not solely driven by comorbidity with
nephropathy. These cross-sectional data are supported by
longitudinal data from the DCCT showing that the inci-
dence of nephropathy and retinopathy are indeed higher in
patients with short stature.
A potential association between adult stature and dia-
betic nephropathy was proposed by Rossing et al. (11),
who reported that patients with type 1 diabetes and
diabetic nephropathy were shorter than those without
nephropathy. However, the ﬁnding was conﬁned only to
male patients. This observation was later challenged by
the EURODIAB Study, which also showed an association
between short adult stature and diabetic nephropathy in
male patients (12); however, the authors concluded that
the association was because of confounding by social
class. Before these studies, a small study in 181 patients
with type 1 diabetes had suggested that short stature was
associated with both nephropathy and retinopathy (17). In
subsequent longitudinal studies, stature has (18) and has
not (19) been associated with development of micro- and
macroalbuminuria in type 1 diabetes. In type 2 diabetes,
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FIG. 1. A: Prevalence (%) of diabetic nephropathy (macroalbuminuria, dialysis, or renal transplantation) in FinnDiane by quartile of height and
decade of birth. ORs (95% CI) for nephropathy per quartile of height are given for each decade of birth. NA, not applicable. B: Prevalence (%)
of laser-treated retinopathy in FinnDiane by quartile of height and decade of birth. ORs (95% CI) for retinopathy per quartile of height are given
for each decade of birth. C: Prevalence (%) of laser-treated retinopathy in FinnDiane by quartile of height and decade of birth. Patients with
diabetic nephropathy (macroalbuminuria, dialysis, or renal transplantation) were excluded from the analyses. ORs (95% CI) for retinopathy per
quartile of height are given for each decade of birth. D: Prevalence (%) of diabetic nephropathy (macroalbuminuria, dialysis, or renal
transplantation) in FinnDiane by groups of age at onset of diabetes. ORs (95% CI) for nephropathy per quartile of height are given for each
decade of birth.
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is also the case for healthy nondiabetic men (21). In
contrast, diabetic peripheral neuropathy has been shown
to be more common among tall patients (22,23), a ﬁnding
also seen in the DCCT cohort of the present study. This
has been interpreted to be because of a greater axon area
exposed to the neurotoxic effects of diabetes.
There is evidence suggesting that adult height is associ-
ated with health outcomes, and short stature has not only
been associated with metabolic disorders but also with
hypertension and CVD. It has, however, been debated
whether these associations are simply because of socio-
economic factors because social status and stature are
positively correlated (24). The observation of a clear
association between short stature and coronary heart
disease in the socially homogeneous Physicians Health
(25) and Helsinki Businessmen (26) studies would argue
against confounding by social class as an alternative
explanation for the association. In our analysis, the asso-
ciations of height with microvascular complications were
independent of social class. Although we cannot exclude
residual confounding, these results do make it more likely
that the observed association is a manifestation of a true
etiological relationship.
It is unlikely that height is a causal factor regarding
diabetic nephropathy or retinopathy, but may be a marker
of an underlying process that confers increased risk. Short
stature could, for example, be secondary to renal os-
teodystrophy, but this cannot explain the difference in
stature seen in the early course of renal disease observed
in our study in which patients with microalbuminuria were
shorter than those with normal UAER. We cannot rule out
common genetic factors, such as IGF-1, that could be
associated both with stature and with diabetic complica-
tions. The association between short stature and renal
disease has previously been hypothesized to reﬂect a
decreased number of nephrons (11,27).
In the FinnDiane Study, short stature was associated
with an overall disadvantageous risk factor proﬁle such as
glycemic control, insulin sensitivity, and serum lipids.
Even in patients with normal UAER, insulin dose and A1C
were similarly associated with stature (results not shown).
TABLE 3
Clinical characteristics by quartiles of height in the DCCT
Quartile
Unadjusted P
P adjusted for
duration of
diabetes 1st 2nd 3rd 4th
Number of patients 310 305 326 305 NA NA
Baseline data
Age (years) 27.6  5.7 29.0  5.7 29.0  5.6 29.1  5.5 1  10
2 NA
Sex (% men) 53.9 53.4 54.9 51.5 0.86 NA
Race (% white) 94.8 96.4 97.5 98.4 0.07 NA
Hollingshead social class
score 26 (15–44) 22 (15–40) 26 (15–43) 22 (15–43) 0.09 0.10
Ever smoke (%) 32.3 23.9 26.4 23.6 0.06 0.03
Age at onset of diabetes
(years) 21.1  7.4 23.5  7.1 23.4  7.0 23.6  6.8 1  10
3 NA
Duration of diabetes
(years) 6.5  4.4 5.5  4.3 5.7  4.2 5.4  4.1 1  10
2 NA
A1C (%) 8.9  1.6 8.7  1.5 8.7  1.5 8.8  1.5 0.29 0.27
Insulin dose (IU/kg) 0.66  0.22 0.61  0.21 0.62  0.20 0.59  0.20 1  10
3 1  10
2
Total cholesterol (mg/dl) 179  34 180  33 180  34 174  31 0.07 0.07
LDL cholesterol (mg/dl) 112  29 113  29 113  30 107  27 0.03 0.04
Systolic blood pressure
(mmHg) 114  12 114  12 115  12 116  11 0.07 0.05
Diastolic blood pressure
(mmHg) 72  97 3  97 4  87 3  9 0.14 0.11
BMI (kg/m
2) 23.8  2.8 23.7  2.8 23.5  2.6 23.5  2.8 0.37 0.42
UAER (mg/24 h) 10.1 (5.8–20.2) 10.1 (5.8–15.8) 10.1 (5.8–15.8) 11.5 (7.2–20.2) 1  10
2 1  10
2
Creatinine clearance
(ml/min per 1.73 m
2) 126  30 124  26 125  27 124  26 0.64 0.68
Nephropathy class 3 (%) 2.3 1.3 1.2 1.0 0.56 0.32
ETDRS retinopathy step
6 (%) 7.1 6.6 3.1 4.3 0.07 0.24
Neuropathy, analytic
deﬁnition (%) 4.8 4.3 9.8 8.9 0.01 1  10
2
Follow-up data (at close-out)
Nephropathy class 4–6 (%) 8.4 3.0 1.8 4.6 1  10
3 0.048
ETDRS retinopathy step
6 (%) 21.8 14.2 14.6 13.2 0.02 0.10
ETDRS retinopathy step
12 (%) 6.3 3.3 1.9 3.6 0.03 0.21
Neuropathy, analytic
deﬁnition (%) 11.1 12.3 15.0 18.2 0.06 1  10
2
Cardiovascular event (%) 8.1 4.9 5.8 7.9 0.31 0.81
Data are means  SD, median (interquartile range), or percentage as appropriate. NA, not applicable.
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also higher in short patients despite no differences in
obesity. These consistent associations between short stat-
ure and features of insulin resistance are noteworthy,
because insulin resistance, and especially pathway-spe-
ciﬁc insulin resistance, has been implicated in the patho-
genesis of diabetic microvascular complications (28).
Impaired growth and development in utero and during
early childhood may lead to metabolic diseases in adult-
hood, and these frequently include features of insulin
resistance (6), thereby providing a possible link between
growth, ﬁnal stature, and diabetic complications. Birth
weight, however, was not previously associated with dia-
betic nephropathy in the FinnDiane Study (29), in contrast
to other studies (30,31), even though an association be-
tween birth weight and adult height was seen (29).
Childhood growth may also be impaired by inadequately
controlled diabetes, and in the present study, earlier age at
onset of diabetes was associated with shorter adult height.
This may indicate that exposure to diabetes in childhood
may translate into both shorter adult height and increased
risk of future complications, possibly because of “meta-
bolic memory” (32). Some support for this was seen in the
FinnDiane Study, where duration of exposure to diabetes
during the years of linear growth (i.e., 18 years) ap-
peared to account for much of the association between
shorter height and microvascular complications. Con-
versely, in both FinnDiane and DCCT, similar associations
or trends with shorter adult height were also seen, even in
patients with onset of diabetes older than 18 years, indi-
cating that childhood exposure to diabetes is not the only
explanation. The proportions of patients that developed
diabetes before the age of 18 years were different between
the FinnDiane (67.4%) and DCCT studies (25.6%), and
these cohorts consequently differed in their power to
detect associations within each age-at-onset subgroup. We
postulate that two main mechanisms are in play: one
through childhood exposure to diabetes and secondly a
common soil hypothesis, that is, that the same factors lead
to both shorter adult height and increased risk of diabetic
complications.
This study has some limitations. We do not have data on
childhood growth and pubertal development that could
have provided insights into the interaction between
growth and complications from type 1 diabetes. The
cross-sectional nature of the data in FinnDiane is a theo-
retical limitation, although the likelihood of reverse cau-
sation is low. In addition, the data from DCCT suggest that
the direction of causality is such that height precedes the
diabetic complications. The associations between stature
and diabetic complications could still be confounded by
factors we have not considered or by imperfect measure-
ment of those confounders that have been included in our
analysis.
In conclusion, this study indicates that short adult
stature is associated with higher prevalence and incidence
of microvascular complications in patients with type 1
diabetes. Understanding the mechanisms underlying these
associations could identify novel preventative strategies.
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